Recent disclosures of clinical candidates (SMR award lecture) highlights from the society for medicines research symposium, held on December 5th 2012 at the national heart & lung institute (NHLI), London, UK

Drugs of the Future

Volumn 38, Issue 2, 2013, Pages 127-133

  Brunavs, M ^a   Cowley, P ^b   Ward, S E ^c   Weber, P ^d  

^a ELI LILLY AND COMPANY   (United States)

^b TPP Global Development   (United Kingdom)

^c UNIVERSITY OF SUSSEX   (United Kingdom)

^d VERTEX PHARMACEUTICALS   (United States)

Author keywords

Asthma; Cancer; Cognitive impairment; Diabetes; Diabetic nephro pathy; Glucokinase activators; Telaprevir

Indexed keywords

ANTIDIABETIC AGENT; ANTINEOPLASTIC AGENT; AZD 1092; BAY 607550; EMD 1214063; GKA 60; INCIVEC; MK 3102; MONOCYTE CHEMOTACTIC PROTEIN 1 INHIBITOR; NOX E 36; OMARIGLIPTIN; PEGINTERFERON ALPHA; PHOSPHODIESTERASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; RAMATROBAN; RIBAVIRIN; SETIPIPRANT; SITAGLIPTIN; TELAPREVIR; UNCLASSIFIED DRUG;

ALLERGIC RHINITIS; ASTHMA; CLINICAL TRIAL (TOPIC); CONFERENCE PAPER; DOSE RESPONSE; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG RESEARCH; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; HEPATITIS C; HUMAN; IC 50; KIDNEY CARCINOMA; LUNG CANCER; MEDICAL SOCIETY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; STRUCTURE ACTIVITY RELATION; UNSPECIFIED SIDE EFFECT;

EID: 84930537845     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2013.038.02.1928559     Document Type: Conference Paper

References (13)

1. Pike, K.G., Allen, J.V., Caulkett, P.W.R. et al. Design of a potent, soluble glucokinase activator with increased pharmacokinetic half-life. Bioorg Med Chem Lett 2011, 21(11): 3467-70.
2. Waring, M.J., Brogan, I.J., Coghlan, M. et al. Overcoming retinoic acid receptor-α based testicular toxicity in the optimisation of glucokinase activators. Med Chem Commun 2011, 2: 771-4.
3. Waring, M.J., Johnstone, C. A quantitative assessment of hERG liability as a function of lipophilicity. Bioorg Med Chem Lett 2007, 17(6): 1759-64.
4. Waring, M.J., Clarke, D.S., Fenwick, M.D. et al. Property based optimisation of glucokinase activators - Discovery of the phase IIb clinical candidate AZD1656. Med Chem Commun 2012, 3: 1077-81.
5. Sugimoto, H., Shichijo, M., Iino, T. et al. An orally bioavailable small molecule antagonist of CRTH2, ramatroban (BAY u3405), inhibits prostaglandin D2-induced eosinophil migration in vitro. J Pharmacol Exp Ther 2003, 305(1): 347-52.
6. Pothier, J., Riederer, M.A., Peter, O., Leroy, X., Valdenaire, A., Gnerre, C., Fretz, H. Novel 2-(2-(benzylthio)-1H-benzo[d]imidazol-1-yl)acetic acids: Discovery and hit-to-lead evolution of a selective CRTh2 receptor antagonist chemotype. Bioorg Med Chem Lett 2012, 22(14): 4660-4.
7. Giunti, S., Barutta, F., Perin, P.C., Gruden, G. Targeting the MCP-1/CCR2 system in diabetic kidney disease. Curr Vascular Pharmacol 2010, 8(6): 849-60.
8. Jarosch, F., Buchner, K., Klussmann, S. In vitro selection using a dual RNA library that allows primerless selection. Nucleic Acids Res 2006, 34(12): e86/1-9.
9. Darisipudi, M.N., Kulkarni, O.P., Sayyed, S.G. et al. Dual blockade of the homeostatic chemokine CXCL 12 and the proinflammatory chemokine CCL2 has additive protective effects on diabetic kidney disease. Am J Pathol 2011, 179(1): 116-24.
10. Kwong, A.D., Kauffman, R.S., Hurter, P., Mueller, P. Discovery and development of telaprevir: An NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus. Nat Biotechnol 2011, 29(11): 993-1003.
11. Perni, R.B., Britt, S.D., Court, J.C. et al. Inhibitors of hepatitis C virus NS3·4A protease 1. Non-charged tetrapeptide variants. Bioorg Med Chem Lett 2003, 13(22): 4059-63.
12. Wager, T.T., Hou, X., Verhoest, P.R., Villalobos, A. Moving beyond rules: The development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties. ACS Chem Neurosci 2010, 1(6): 435-49.
13. Wager, T.T., Chandrasekaran, R.Y., Hou, X., Troutman, M.D., Verhoest, P.R., Villalobos, A., Will, Y. Defining desirable central nervous system drug space through the alignment of molecular properties, in vitro ADME, and safety attributes. ACS Chem Neurosci 2010, 1(6): 420-34.